Heather S. Han, MD

Heather ​S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Heather ​S. Han, MD, discusses the importance of risk stratification in HER2-positive breast cancer.

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.

Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.